Skip to main content
logo
Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
7.54
-0.13 (-1.69%)
Oct 19, 2026, 11:36 AM EDT - Market open

Atrium Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Income
-65.99-49.5-25.12-6.39
Depreciation & Amortization
0.690.320.170.14
Loss (Gain) From Sale of Assets
0.140.14--
Stock-Based Compensation
17.887.683.182.51
Other Operating Activities
1.890.4312.110.2
Change in Accounts Receivable
--0.751.39
Change in Accounts Payable
3.063.730.03-0.05
Change in Unearned Revenue
-10.84-8.62-10.1162.78
Change in Other Net Operating Assets
0.244.69-3.56-4.19
Operating Cash Flow
-53.19-41.13-22.5556.39
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Capital Expenditures
-3.31-1.45-0.27-0.32
Investing Cash Flow
-194.86-1.45-0.27-0.32

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Other Financing Activities
320.842.5722.82-56.07
Financing Cash Flow
320.842.5722.82-56.07

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-56.5-42.57-22.8256.07
Free Cash Flow Growth
----
Free Cash Flow Margin
-157.66%-228.67%-209.41%574.25%
Free Cash Flow Per Share
-3.30-2.74--
Levered Free Cash Flow
--11.65-12.01-
Unlevered Free Cash Flow
--11.65-12.01-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Change in Working Capital
-7.54-0.2-12.8959.94